Denis Hadjiliadis

Denis Hadjiliadis

Auto-generated profile, based on publicly available information

Denis Hadjiliadis

University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RRR. Reshef
R. Reshef
SVS. Vardhanabhuti
S. Vardhanabhuti
MLM. R. Luskin
M. R. Luskin
DHD. F. Heitjan
D. F. Heitjan
DHD. Hadjiliadis
D. Hadjiliadis
DTD. E. Tsai
D. E. Tsai
Reduction of immunosuppression (RI) is commonly used to treat posttransplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients. We investigated the efficacy, safety and predictors of response to RI in adult patients with PTLD. Sixty‐seven patients were managed with RI alone and 30 patients were treated with surgical excision followed by adjuvant RI. The response rate to RI alone was 45% (complete response—37%, partial response—8%). The relapse rate in complete responders was 17%. Adjuvant RI resulted in a 27% relapse rate. The acute rejection rate following RI‐containing strategies was 32% and a second transplant was feasible without relapse of PTLD. The median survival was 44 months in patients treated with RI alone and 9.5 months in patients who remained on full immunosuppression (p = 0.07). Bulky disease, advanced stage and older age predicted lack of response to RI. Survival analysis demonstrated predictors of poor outcome—age, dyspnea, B symptoms, LDH level, hepatitis C, bone marrow and liver involvement. Patients with none or one of these factors had a 3‐year overall survival of 100% and 79%, respectively. These findings support the use of RI alone in low‐risk PTLD and suggest factors that predict response and survival.

1 February 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
DHDenis Hadjiliadis
Denis Hadjiliadis
AKAlexander Khoruts
Alexander Khoruts
AZAnn G. Zauber
Ann G. Zauber
SHSarah E. Hempstead
Sarah E. Hempstead
PMPatrick Maisonneuve
Patrick Maisonneuve
KSKathy Sabadosa
Kathy Sabadosa

1 August 2007 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DHDenis Hadjiliadis
Denis Hadjiliadis
MSMark P. Steele
Mark P. Steele
CCCecilia Chaparro
Cecilia Chaparro
LSLianne G. Singer
Lianne G. Singer
TWThomas K. Waddell
Thomas K. Waddell
SKShaf Keshavjee
Shaf Keshavjee

23 April 2007 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CGC. Gutierrez
C. Gutierrez
SAS. Al-Faifi
S. Al-Faifi
CCC. Chaparro
C. Chaparro
TWT. Waddell
T. Waddell
DHD. Hadjiliadis
D. Hadjiliadis
MHM. Hutcheon
M. Hutcheon
Selection criteria for organ transplantation have evolved over time. Age has been revisited periodically. We studied the outcome of lung transplant adjusted by age in a single center transplant population. We matched the 42 lung graft recipients older than 60 years transplanted by July 1999 to younger controls by lung disease, transplant era within 2 years, type of transplant and gender. The female to male ratios were 17/25 among the older cohort (median age 61.6 years), and 15/27 (median age 51.9 years) among the matched younger. Survival analysis demonstrated a significant difference: at 1 year, 60% versus 86%, and at 5 years, 37% versus 57%, for older and younger, respectively, p = 0.005. Excess annual mortality, calculated with the declining exponential approximation to life expectancy (DEALE), showed an older/younger ratio of 1.9. Eleven deaths occurred within 6 months among the older patients, 10 due to infection. After 6 months, there were 20 more deaths, 6 due to malignancy, 5 to Bronchiolitis Obliterans Syndrome (BOS), 3 to infection and 6 to other causes. Among the younger there were 6 deaths within 6 months and 12 more thereafter; among the latter, 8 were due to BOS. Despite stringent selection, lung transplant recipients older than 60 years show increased mortality even after adjusting for their expected higher age-related mortality.

24 August 2005 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
DHDenis Hadjiliadis
Denis Hadjiliadis
JMJanet Madill
Janet Madill
CCCecilia Chaparro
Cecilia Chaparro
ATAnna Tsang
Anna Tsang
TWThomas K Waddell
Thomas K Waddell
DTD Elizabeth Tullis
D Elizabeth Tullis

1 September 2017 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
GSGregory Snell
Gregory Snell
ARAnna Reed
Anna Reed
MSMarc Stern
Marc Stern
DHDenis Hadjiliadis
Denis Hadjiliadis